Core Viewpoint - The report highlights the steady growth of Daodaoquan's core business and the effectiveness of its channel expansion, leading to a "buy" rating from Southwest Securities [1]. Financial Performance - In the first half of 2025, Daodaoquan achieved revenue of 2.792 billion yuan, a year-on-year increase of 1.16% - The net profit attributable to shareholders reached 181 million yuan, up 563.15% - The net profit after deducting non-recurring items was 157 million yuan, an increase of 428.51% [1][2]. Cost Management and Profitability - The company benefited from a decline in raw material costs, significantly restoring profitability - The overall gross margin improved by 2.32 percentage points to 11.65% - The gross margin for the core product, packaging oil, increased by 0.89 percentage points to 15.67%, while the gross margin for meal products rose by 1.23 percentage points to 5.40% [1][2]. Core Business Growth - The packaging oil business, which is the main source of revenue and profit, generated 1.751 billion yuan, a year-on-year increase of 20.53% - Sales volume in the food processing segment reached 170,900 tons, up 24.19%, indicating strong market demand and brand recognition - The number of distributors increased by 92 to 1,397, and online direct sales revenue for packaging oil grew by 23.64% [2]. Capacity Expansion - Daodaoquan plans to invest 1 billion yuan in a 1 million tons/year edible oil processing project in Weinan, Shaanxi, to capture opportunities in the Northwest market - The company is also advancing the construction of the "Daodaoquan Changsha Headquarters Base" with an investment of 45 million yuan during the reporting period, totaling 228 million yuan [2]. Earnings Forecast - The expected EPS for 2025, 2026, and 2027 are 0.7 yuan, 0.83 yuan, and 1.02 yuan, respectively - The corresponding dynamic PE ratios for 2025-2027 are projected to be 16, 14, and 11 times [3].

（文章来源：每日经济新闻） 西南证券8月4日发布研报称，给予宁德时代（300750.SZ，最新价：266.48元）买入评级。评级理由主 要包括：1）费用控制较Q1有所提升，净利率创新高；2）港交所挂牌加快全球化战略布局，持续推出 创新产品，夯实其寡头地位。风险提示：宏观经济与市场波动风险；市场竞争加剧风险；新产品和新技 术开发风险；原材料价格波动及供应风险。 ...

Industry Insights - The supply-demand gap in the copper industry is expanding, indicating a long-term upward trend in copper prices [2] - The company is experiencing an increase in both copper production and prices, with the Yulong Copper Mine being a significant source of profit [2] - The third phase of the Yulong project is actively progressing [2] Company Analysis - Southwest Securities has issued a "buy" rating for Western Mining (601168.SH) with a latest price of 17.28 yuan [2]

Group 1 - The company has signed a sales agreement with GF Securities to start selling certain funds from August 4, 2025 [1] - The announcement includes details about the applicable funds and their business opening status, indicating that the ability to conduct regular investment and conversion business depends on the sales institution's arrangements [1][2] - Investors can inquire about details through the customer service of both the company and GF Securities [4][5] Group 2 - The company has announced that GF Securities will serve as a sales agent for certain funds, with specific operational details provided [2][3] - The company has also added Southwest Securities as a primary trading dealer for some of its funds, effective from August 4, 2025 [7][8] - The announcement includes the contact information for Southwest Securities, emphasizing the importance of investor inquiries for further details [8]

Group 1 - The core viewpoint of the report is that Dongpeng Beverage (605499.SH) is rated as a "buy" due to its solid foundation in energy drinks and rapid growth in electrolyte water [2] - The company is making steady progress in its national expansion and is continuously strengthening its platform-based foundation [2] - Cost advantages and economies of scale are resonating, leading to increased expenditure on marketing and promotions [2]

（文章来源：每日经济新闻） 西南证券7月31日发布研报称，给予国邦医药（605507.SH，最新价：23.25元）买入评级。评级理由主 要包括：1）点评：医药与动保双轮驱动，市场需求稳定增长；2）双轮驱动，医药与动保业务协同发 展；3）全球化布局与高附加值产品战略推动市场竞争力提升；4）持续加大研发投入，技术创新驱动未 来发展。风险提示：项目建设或不及预期；产品销售情况或不及预期；养殖业突发疫情的风险等。 ...

（文章来源：每日经济新闻） 西南证券7月31日发布研报称，给予海思科（002653.SZ，最新价：55.79元）买入评级。评级理由主要 包括：1）HSK21542注射液"骨科镇痛"适应症开启III期临床试验；2）中国骨科镇痛市场需求刚性；3） 该药已启动4项III期临床。风险提示：市场竞争风险、药品价格下行风险、新药研发风险。 ...

Group 1 - The core viewpoint of the report highlights the impressive year-on-year growth in revenue and profit for WuXi AppTec in Q2 [2] - The revenue growth of small molecule drug development (DM) exceeded expectations, while TIDES continued to show strong growth [2] - The laboratory business remained stable, although competition in the clinical CRO market continues to be a factor that needs to be addressed [2]

今日爱柯迪（600933）涨5.52%，收盘报17.0元。 2025年5月2日，西南证券研究员郑连声,张雪晴发布了对爱柯迪的研报《Q1业绩稳健增长，机器人业务 进一步拓展》，该研报对爱柯迪给出"买入"评级。研报中预计公司2025-2027年EPS为1.17/1.36/1.50元， 三年归母净利润年复合增速达16.4%。公司产品结构优化，全球化布局加速，新建产能释放，业绩具备 向上空间，维持"买入"评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的 盈利预测准确度为80.25%。 此外，民生证券研究员崔琰,姜煦洲，东吴证券研究员黄细里,郭雨蒙近期也对该股发布了研报，同样给 出"买入"评级。 证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信建投证券的杨耀先。 爱柯迪（600933）个股概况： | 财务摘要 | 爱柯迪2025年一季报显示，公司主营收入16.66亿元，同比上升1.41%；归母 净利润2.57亿元，同比上升10.94%；扣非净利润2.36亿元，同比上升6.64%； | | --- | --- | | | 负债率41.19%，投资收益1400.04万元,财务费用-569 ...

近日，新浪财经首届上市券商领军人物领导力TOP榜结果出炉，西南证券总经理杨雨松获成长发展券商第 25名。 "上市券商领军人物领导力TOP榜"由新浪财经发起，旨在表彰各大券商领军人物的卓越贡献与深远影响 力。该榜单盘点最近一个完整年度的券商领袖管理成就，以行业数据、同业评价、网络声量多维度综合评 价体系为基础，以创造经济与社会价值为核心标准，表彰杰出领袖，助力金融行业持续健康发展。 个人简介 杨雨松 注释:基础数据来源于财务报告,排名数据统计以上市券商为主（约50家左右）, 数据网状图为本公司各业务数据横向比较。 | 机构同业评价(权重40%) | | | | --- | --- | --- | | 前瞻力 控制力 创新力 | 合规性 | 影响力 | | 78.80分 79.86分 78.77分 78.62分 71.15分 | | | | 评审委员会: | | | 由券商研究所、独立财富管理机构、媒体等高级管理人员组成。 1972年6月出生，管理学硕士，高级经济师。 现任西南证券党委副书记、董事、总经理。曾任职于华夏证券有限公司、重庆港九股份有限公司、重庆渝 富资产经营管理集团有限公司（现重庆渝富资本运营集团有 ...